CN1250228C - Orally disintegrating tablet of notoginsen total saponins and its preparation - Google Patents
Orally disintegrating tablet of notoginsen total saponins and its preparation Download PDFInfo
- Publication number
- CN1250228C CN1250228C CNB2004100497769A CN200410049776A CN1250228C CN 1250228 C CN1250228 C CN 1250228C CN B2004100497769 A CNB2004100497769 A CN B2004100497769A CN 200410049776 A CN200410049776 A CN 200410049776A CN 1250228 C CN1250228 C CN 1250228C
- Authority
- CN
- China
- Prior art keywords
- radix notoginseng
- parts
- tablet
- preparation
- disintegrating tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a pharmaceutical preparation for treating cardio-cerebrovascular system diseases, particularly a panax notoginseng saponins orally disintegrating tablet for treating cerebrovascular blockage and stasis, apoplexy and hemiplegia, heart vessel blockage and stasis, thoracic obstruction and cardiodynia, cerebrovascular disease sequelae, coronary heart disease, angina pectoris and other diseases, which is prepared from panax notoginseng saponins as a raw material, and auxiliary materials, comprising a filling agent, a disintegrating agent, glidant, a lubricant, etc., by a specific preparation method; a binding agent, a capsule material or a coating material can be added according to different circumstances, and a right quantity of an effervescing agent can also be added according to the circumstances. The pharmaceutical preparation has the characteristics of simple preparation technologies, no need of water during adminitration, direct disintegration of the orally disintegrating tablet in oral cavities and no obvious sand gravel sensation, and the orally disintegrating tablet can be admitted by the aid of swallows. Thus, the pharmaceutical preparation is especially suitable for a plurality of emergency patients with dysphagia or in specific environments, comprising the elderly, children, stuporous patients, etc.; the disintegration time is short, and the orally disintegrating tablet can be completely disintegrated with 60 seconds in general. Thus, the orally disintegrating tablet is favorable to the dissolution of medicines for absorption, and can take effect rapidly.
Description
[technical field] the present invention relates to a kind ofly have blood circulation promoting and blood stasis dispelling, the effects such as active, anticoagulant and cerebral blood flow increasing amount of promoting blood circulation, and is used for the treatment of the stasis of blood resistance of brain road, apoplectic hemiplegia, heart arteries and veins stasis of blood the moon, obstruction of qi in the chest and cardialgia; Apoplexy sequela, a kind of oral cavity disintegration tablet of diseases such as angina pectoris.
[background technology] Radix Notoginseng is the araliaceae ginseng plant, is Chinese distinctive rare Chinese medicine.Radix Notoginseng originates from mountain area, ancient subtropical zone in the Tertiary Period before 2,500 ten thousand, because its environmental condition to growth has specific (special) requirements, now exists only in the Southwest China mountain area.According to relevant document record, Radix Notoginseng was used historical nearly 600 years, nearly 500 years of cultivation history.Radix Notoginseng is because of it has significant blood circulation promoting and blood stasis dispelling with regard to being acknowledged as since ancient times, the subduing swelling and relieving pain effect is described as " Radix Stephaniae Sinicae (Radix Stephaniae Dielsianae) ", " southern part of the country SHENCAO ".In recent years mostly with Radix Notoginseng total arasaponins as raw material, adopt modern preparation technique to make various different dosage forms, use to make things convenient for extensive patients and medical personnel.
One, principal agent active component and pharmacological effect
The chemical constituent kind of Radix Notoginseng total arasaponins is more, mainly is divided into tetracyclic triterpene dammarane type protopanoxadiol saponins and tetracyclic triterpene dammarane type Protopanaxatriol saponins two big classes.Its principal agent composition and corresponding main pharmacological effect thereof are as follows.
Tetracyclic triterpene dammarane type protopanoxadiol saponins has:
The ginsenoside Rb1 promotes the formation of nerve fiber and keeps its function, prevents sexual hypofunction, the inhibition central nervous system, and calmness is slept peacefully, and is analgesic, promotes serum albumin synthetic, promotes cholesteric synthetic and decomposition, suppresses neutral fat and decomposes anti-hemolysis;
The panaxosideRb2 suppresses nervus centralis, promotes DNA, and RNA is synthetic, anti-hemolysis, anti-diabetic;
Ginsenoside Rc suppresses nervus centralis, promotes DNA, and RNA is synthetic, promotes serum albumin synthetic;
The ginsenoside Rd raise immunity, anticancer is grown up;
Ginsenoside Rh 2 promotes that cancerous cell transformation is non-cancerous cell.Tetracyclic triterpene dammarane type Protopanaxatriol saponins has:
The ginsenoside Re suppresses nervus centralis, promotes DNA, and RNA is synthetic;
The ginsenoside Rg1 stimulating central nervous system prevents sexual hypofunction, and hypermnesis sets up, and promotes DNA, and RNA is synthetic, anti-platelet aggregation;
Panaxoside Rg 2 anti-platelet aggregations;
Ginsenoside Rh1 promotes that cancerous cell transformation is non-cancerous cell;
Arasaponin R1 inducing leukemia cell differentiation.
Two, clinical practice
1. to the effect of blood and hemopoietic system
1. Radix Notoginseng has good hemostasia effect, can obviously shorten hemorrhage and clotting time.
Utilize Radix Notoginseng treat various traumatic hemorrhage, various in mass formed by blood stasis be used widely clinically.
2. Radix Notoginseng can promote all kinds of hemocyte merisis, increase number, has remarkable nourishing blood function.
Test finds that Radix Notoginseng can obviously be improved the erythrocyte quantity of hemorrhagic anemia pathological model (rat and rabbit), and hemorrhagic anemia is had treatment preferably.
Radix Notoginseng total arasaponins the total white blood cells, can also significantly improve the macrophage phagocytic rate in improving the white mouse peripheral blood, improve the percentage ratio of blood medium-sized lymphocyte.
3. Radix Notoginseng has the obvious curative effects of blood circulation promoting and blood stasis dispelling, eliminating blood stasis to promote regeneration of blood.
Experiment shows that the aortic tunica intima speckle that Radix Notoginseng total arasaponins can significantly suppress the experimental atherosclerosis rabbit forms.
2. to the effect of cardiovascular system
Experiment shows, Radix Notoginseng is at obvious blood vessel dilating, lower coronary resistance, increase coronary flow, tighten and improve the arteria coronaria microcirculation, in the time of having additional nutrients property myocardial flow, can reduce arterial pressure, slightly subtract heart rate, the heart working amount is lowered, thereby obviously reduce the oxygen consumption of cardiac muscle, can be used for treating myocardial ischemia, angina pectoris and shock.
Experiment showed, that Radix Notoginseng total arasaponins all has to a certain degree antagonism to kinds of experiments arrhythmia model.
It is reported that with raw sangqi ginseng sheet treatment coronary disease sufferer, total effective rate reaches 97%, wherein obvious effective rate 42.5%.
3. to neural effect
Studies show that, both contained protopanoxadiol type saponin in the Radix Notoginseng, also contain Protopanaxatriol's type saponin, wherein: protopanoxadiol type saponin has the central nerve inhibition effect; Protopanaxatriol's type saponin has the central nervous excitation effect.
Clinical practice proves that Radix Notoginseng part centering pivot nerve on the ground has inhibitory action, shows as calmness, stabilizes and improve functions such as sleep; Radix Notoginseng under ground portion energy stimulating central nervous system improves mentality and physical, shows fatigue resistance; The various piece of Radix Notoginseng all helps strengthening the learning and memory ability, and has significant analgesia role.
4. anti-inflammatory effect
Pharmacological evaluation shows that Radix Notoginseng has the obvious suppression effect to the vascular permeability increase that multiple reason causes, has stronger anti-inflammatory efficacy.For example: Radix Notoginseng is planted the granuloma that connective tissue proliferation inflammation that cotton balls causes and cotton balls cause very obvious suppression effect is arranged for rat back is subcutaneous; Mice auricle swelling due to mice arthroncus that Radix Notoginseng total arasaponins on Carrageenan, hyalomitome enzyme cause and Oleum Tiglii, the dimethylbenzene has the obvious suppression effect.
Clinical practice shows: Radix Notoginseng treatment open fracture, and the reducing swelling and alleviating pain effect is excellent; After musk-zengusui was improved to the Radix Notoginseng bone-setting liquor, effect obviously improved.
5. Radix Notoginseng is to immune function
Pharmacological evaluation finds that Radix Notoginseng total arasaponins can significantly improve the phagocytic rate and the phagocytic index of the macrophage of mice, improves total white blood cells in the peripheral blood, reduces leukocytic movement index; Pseudo-ginseng water decoct or Radix Notoginseng polysaccharide have obvious facilitation to mice body endoantigen in conjunction with the generation of cell; Arasaponin has facilitation at external mitosis to human lymphocyte.
In sum, Radix Notoginseng has certain immunoregulation effect.
6. the antitumor action of Radix Notoginseng
In recent years, Chinese scholars has obtained gratifying progress to antitumor (cancer) the effect research of Radix Notoginseng.
Studies show that, contain anti-cancer active matters such as arasaponin, beta-elemene, trace element-selenium in the Radix Notoginseng; The Rb1 of arasaponin 120ug/ml concentration can make the tumor cell 92% of cultivation be suppressed, and the suppression ratio of Panax Notoginseng saponin R d then is 79%; Panax Notoginseng saponin R h1 has the obvious suppression effect to the hepatoma carcinoma cell of cultivating; Panax Notoginseng saponin R h2 has stronger anti-tumor activity, and can be reversed into non-cancerous cell by inducing cancer cell.
In addition, arasaponin and Radix Notoginseng polysaccharide energy enhancing human body immunity function have certain assosting effect to the treatment cancer.
7. antioxidation delays anti-aging effects
The abnormal accumulation of body inner lipid peroxide (LPO) is the one of the main reasons of human senility.
Experiment showed, that Radix Notoginseng can obviously improve the activity of the SOD in rat cerebral tissue and the blood, significantly reduce the content of Lpo in cerebral tissue and the blood, have anti-aging effects.
Three, the problem of Cun Zaiing
The dosage form of existing Radix Notoginseng total arasaponins preparation has: drop pill, hard capsule, soft capsule, injection, dispersible tablet and ordinary tablet.
Because dosage form needs a large amount of water to send down when most of oral formulations are taken, this makes the patient of many old peoples, infant or dysphagia, water intaking inconvenience be difficult to take.Injection often is easy to generate anaphylaxis or untoward reaction etc. again, and it is big that the while injection also exists operation easier, and the patient suffering is also big, makes and medical treatment cost high the shortcoming that patient economy burden is heavy.Therefore, be necessary to prepare and take convenient dosage form to satisfy the multiple needs that clinical treatment and family use.
[summary of the invention] the objective of the invention is to remedy the deficiency of existing Radix Notoginseng total arasaponins dosage form, provide to extensive patients and medical personnel that a kind of absorption is fast, bioavailability is high, intestinal is residual few, side effect is low, avoid liver first-pass effect, and needn't drink water, in the oral cavity, only need tens seconds to get final product rapid disintegrate or dissolving, can finish oral disintegrant tablet of total arasaponin of taking medicine and preparation method thereof with saliva hypopharynx.
One, prescription
The oral disintegrant tablet of total arasaponin that reaches of the present invention comprises the material medicine Radix Notoginseng total arasaponins, needs following former, the auxiliary material of 9 classes altogether, wherein: when not making Cotton seeds, then do not use coating material, effervescent and binding agent also can for selecting adjuvant for use as one sees fit.
1. Radix Notoginseng total arasaponins (10～50) %, 2. binding agent (0～5) %,
3. filler (10～80) %, 4. coating material (0～50) %,
5. disintegrating agent (2～30) %, 6. correctives (1～40) %,
7. fluidizer (0.01～5) %, 8. lubricant (0.3～3) %,
9. effervescent (0～30) %.
Wherein:
Binding agent---include but are not limited to starch, pregelatinized Starch, dextrin, maltodextrin, sucrose, arabic gum, methylcellulose, carboxymethyl cellulose, ethyl cellulose, polyvinyl alcohol, Polyethylene Glycol, polyvinylpyrrolidone (PVP), alginic acid and alginate, xanthan gum and hydroxypropyl emthylcellulose (HPMC).Coating material---gelatin, arabic gum, alginate, chitosan, carboxymethyl cellulose salt, cellulose acetate phthalate ester, ethyl cellulose, methylcellulose, hypromellose, crylic acid resin (homemade acrylic resin I, II, III, IV, Eudragit
Series), any one or two or more mixture such as polyvinyl alcohol, polyvinylpyrrolidone, Polyethylene Glycol.
Any one or two or more mixture such as filler---mannitol, microcrystalline Cellulose, dextrin, lactose, starch, maltodextrin and pregelatinized Starch;
Disintegrating agent---crospolyvinylpyrrolidone (PPVP), carboxymethyl starch sodium (CMS-Na), low substituted hydroxy-propyl methylcellulose (L-HPC), cross-linking sodium carboxymethyl cellulose (CCNa) wait any one or two or more mixture;
Any one or two or more mixture such as correctives---mannitol, lactose, stevioside, gelatin, aspartame, cyclamate, glycyrrhizin, fragrant citrus essence, flavoring orange essence, Herba Menthae essence, ginseng essence, strawberry essence, citric acid, citric acid;
The mixture of effervescent---citric acid or citric acid and sodium bicarbonate or sodium carbonate.
Any one or two or more mixture such as fluidizer---micropowder silica gel, Pulvis Talci, Cab-O-sil, Arosil, hydrated sodium aluminosilicate;
Any one or two or more mixture such as lubricant---magnesium stearate, glyceryl monostearate, Stepanol MG, Pulvis Talci.
As one of invention embodiment, described oral disintegrant tablet of total arasaponin is made of the supplementary material of following weight portion: 250.0 parts of Radix Notoginseng total arasaponinss, 1019.5 parts in mannitol, Eudragit
40.0 parts of E100, Eudragit
10.0 parts of NE30D, 22.5 parts of micropowder silica gels, 120.0 parts of crospolyvinylpyrrolidone, 8.0 parts of aspartames, 15.0 parts of ginseng essences, 15.0 parts of magnesium stearate, wherein, with Eudragit
E100 and Eudragit
NE30D is a coating material, and Radix Notoginseng total arasaponins makes Radix Notoginseng total arasaponins powder coating granule by powder coating, makes disintegrating tablet with other component mixing, tabletting again.
Two, preparation method
The oral disintegrant tablet of total arasaponin that reaches of the present invention, its preparation method are to adopt common press device and direct compression process technology, and the manufacturer with preparation conventional tablet all can adopt.Adopt the oral cavity disintegration tablet of this method preparation to have enough hardness (intensity), can satisfy the requirement of production, packing, accumulating, have good mouthfeel and short disintegration time simultaneously again.
In view of the Radix Notoginseng total arasaponins mildly bitter flavor, the present invention can adopt two kinds of distinct methods to carry out flavoring or taste masking: adopt the direct flavoring of correctives 1.; 2. in advance Radix Notoginseng total arasaponins is carried out powder coating with taste masking, concrete preparation method is as follows:
The preprocess method of first step Radix Notoginseng total arasaponins:
1. directly the flavoring method---this law does not deal with Radix Notoginseng total arasaponins, directly enters for second step;
2. prefabricated microcapsule taste masking---get selected capsule material, with dissolved in distilled water and be diluted to debita spissitudo, add fluidizer and mix homogeneously, adopt the uprush laggard line space gas suspension legal system that suspends to be equipped with microcapsule with Radix Notoginseng total arasaponins again, gained Radix Notoginseng total arasaponins powder coating granule, dry back is standby;
3. powder coating taste masking---get selected coating material, with the dissolving of the lyase that adapts with it and to be diluted to debita spissitudo standby, getting Radix Notoginseng total arasaponins again places ebullated bed to make boiling, spray into above-mentioned solution with suitable speed then and carry out powder coating, get Radix Notoginseng total arasaponins powder coating granule, dry back sieving for standby;
Second step took by weighing correctives and Radix Notoginseng total arasaponins or the feed particles after first step taste masking processing according to quantity, and mix homogeneously is standby;
The 3rd step took by weighing filler, disintegrating agent, effervescent, fluidizer and mix homogeneously according to quantity, made evenly again with through second mixing of materials that goes on foot gained, and adding lubricant mixing is standby;
The 4th step gained material detects through intermediate, determine that sheet is heavy after, send into the tablet machine tabletting promptly.
[beneficial effect] tablet is a kind of conventional dosage forms, because of its steady quality, dosage accurately, take, easy to carry, mechanization degree is high, low one of the at present the most frequently used dosage form that becomes of production cost, but because of the tablet extrusion forming, disintegrate is slow, bioavailability is lower, and part patient swallows comparatively difficult, thereby promoting the use of to a certain extent of tablet is restricted.The oral administration solid quick releasing formulation becomes a focus, particularly oral cavity disintegration tablet of new drug development in recent years for this reason, because of its taking convenience, rapid-action, bioavailability is high, the good emphasis that becomes tablet exploitation of mouthfeel.
Oral cavity disintegration tablet is meant not to be needed water or only needs low amounts of water, need not to chew, and tablet places lingual surface, meets after saliva separates rapidly or collapse, and borrows and swallows power, and medicine can be gone into the tablet of stomach onset.Oral cavity disintegration tablet needn't be used water delivery service, and saliva can make its disintegrate or dissolving, both can swallow by conventional tablet, can be placed in the water again to take after the disintegrate, also can not need to take medicine with water swallow.Especially provide convenience for old man, children's, dysphagia or the inconvenient person that fetches water take medicine,, then can improve the drug compliance of child patient greatly, solved the problem that it is difficult that infant is taken medicine if adopt certain method to improve its mouthfeel in the preparation.The characteristics of oral cavity disintegration tablet are that absorption is fast, bioavailability is high, intestinal is residual few, side effect is low, avoid liver first-pass effect etc., therefore, oral cavity disintegration tablet is applicable to onset rapidly, and valid density and poisoning concentration differ bigger medicine, and some war wound emergency treatment medicines, NSAID (non-steroidal anti-inflammatory drug), spasmolytic Bendectin and analgesic etc. all relatively are fit to make oral cavity disintegration tablet.Other medicine such as blood drug level are in for a long time than plateau, then easily produce drug resistance, make oral cavity disintegration tablet and then can overcome this problem, produce excellent curative.
According to the disclosed description introduction of No. 03148531.6 patent " FUFANG DANSHEN KOUQIANG BENGJIEPIAN and preparation method ", oral cavity disintegration tablet has the leap of essence than the disintegration rate of drop pill and ordinary tablet, the disintegrate of oral cavity disintegration tablet generally in 30 seconds, is no more than 1 minute at most.And the dissolve scattered time limit of drop pill Chinese Pharmacopoeia regulation is in 30 minutes, and be all molten loosing about 5 minutes the disintegration of conventional tablet Chinese Pharmacopoeia regulation.
The principal indication of Radix Notoginseng total arasaponins is the road stasis of blood resistance of treatment treatment brain, apoplectic hemiplegia, heart arteries and veins stasis of blood the moon, obstruction of qi in the chest and cardialgia; Apoplexy sequela, diseases such as angina pectoris, Most patients is an old group, even there wherein have quite a few patient to swallow food to be not very convenient, and that other most of oral formulations also exist dissolve scattered time limit is long, dissolution is low, absorb relatively poor, problems such as liver sausage first pass effect and bioavailability are lower, add injection again and often be easy to generate anaphylaxis or untoward reaction etc. again, it is big simultaneously yet to exist operation easier, the patient suffering is also big, make and the medical treatment cost height, the shortcoming that patient economy burden is heavy, the Radix Notoginseng total arasaponins Orally-disintegrating tablet that reaches therefore of the present invention, it is more outstanding that its advantage just seems.
[specific embodiment] is in order better to illustrate the preparation method of oral disintegrant tablet of total arasaponin of the present invention, in conjunction with directly flavoring method and powder coating taste masking method are as follows for an embodiment respectively:
Embodiment 1 direct flavoring method
One, prescription
1. raw material---Radix Notoginseng total arasaponins 250.0g;
2. binding agent---PVP-K30 5.0g;
3. filler---lactose 150.0g;
Mannitol 922.0g;
4. fluidizer---micropowder silica gel 15.0g;
5. disintegrating agent---crospolyvinylpyrrolidone 40.0g;
L-HPC 80.0g；
6. correctives---aspartame 8.0g;
Ginseng essence 15.0g;
7. lubricant---magnesium stearate 15.0g;
Gross weight 1500.0g makes 10000, the 150mg/ sheet altogether.
Two, preparation method
The first step is got Radix Notoginseng total arasaponins, does binding agent with PVP-K30, and wet granulation is crossed 20 mesh sieve granulate, and 30 mesh sieve granulate are crossed in oven dry, make the Radix Notoginseng total arasaponins granule, and are standby;
Second step was got the residue adjuvant mix homogeneously except that magnesium stearate, and the Radix Notoginseng total arasaponins granule that will make again adds and mix homogeneously, adds magnesium stearate and mix homogeneously at last;
The 3rd step intermediate content detection, determine that sheet is heavy after, send into the tablet machine tabletting promptly.
Embodiment 2 contains effervescent flavoring method
One, prescription
1. raw material---Radix Notoginseng total arasaponins 250.0g;
2. filler---mannitol 762.0g;
3. effervescent---citric acid 160.0g;
Sodium bicarbonate 140.0g;
4. fluidizer---micropowder silica gel 15.0g;
5. disintegrating agent---crospolyvinylpyrrolidone 120.0g;
6. correctives---aspartame 8.0g;
Fructus Citri tangerinae essence 30.0g;
7. lubricant---magnesium stearate 15.0g;
Gross weight 1500.0g makes 10000, the 150mg/ sheet altogether.
Two, preparation method
The first step is got citric acid and sodium bicarbonate pulverize separately, sifts out 20 order to 60 purpose granules, and is standby;
Second step was got the residue supplementary material mix homogeneously except that magnesium stearate, and citric acid that will make and sodium bicarbonate particle add and mix homogeneously again, add magnesium stearate and mix homogeneously at last;
The 3rd step intermediate content detection, determine that sheet is heavy after, send into the tablet machine tabletting promptly.
Embodiment 3 powder coating taste masking methods
One, prescription
1. raw material---Radix Notoginseng total arasaponins 250.0g;
2. filler---mannitol 1019.5g;
3. coating material---Eudragit
E100 40.0g;
Eudragit
NE30D (doing) 10.0g;
4. fluidizer---micropowder silica gel 22.5g;
5. disintegrating agent---crospolyvinylpyrrolidone 120.0g;
6. correctives---aspartame 8.0g;
Ginseng essence 15.0g;
7. lubricant---magnesium stearate 15.0g;
Gross weight 1500.0g makes 10000, the 150mg/ sheet altogether.
Two, preparation method
The first step is got Eudragit E100 and Eudragit NE30D with the medicinal industrial alcohol dissolving more than 95% and to be diluted to finite concentration standby;
Second step got Radix Notoginseng total arasaponins and places ebullated bed to seethe with excitement, and sprayed into above-mentioned solution by certain speed and carried out powder coating, made Radix Notoginseng total arasaponins powder coating granule, and the 0.6mm sieve is crossed in dry back, and is standby.
The 3rd the step with mannitol, micropowder silica gel, crospolyvinylpyrrolidone, aspartame and ginseng essence mix homogeneously, again and sieve after the coated granule mixing, add magnesium stearate at last, mixing,
The 4th step intermediate content detection, determine that sheet is heavy after, send into the tablet machine tabletting promptly.
Disintegration of the foregoing description and slice, thin piece hardness numerical value are as follows:
| Embodiment | Disintegration (second) | Slice, thin piece hardness (newton) |
| 1 2 3 | ＜43 seconds＜50 seconds＜38 seconds | 17-35 20-33 18-28 |
Claims (3)
1. oral disintegrant tablet of total arasaponin that is used for the treatment of diseases of cardiovascular and cerebrovascular systems is made of the supplementary material of following weight portion: 250.0 parts of Radix Notoginseng total arasaponinss, 1019.5 parts in mannitol, Eudragit
40.0 parts of E100, Eudragit
10.0 parts of NE30D, 22.5 parts of micropowder silica gels, 120.0 parts of crospolyvinylpyrrolidone, 8.0 parts of aspartames, 15.0 parts of ginseng essences, 15.0 parts of magnesium stearate, wherein, with Eudragit
E100 and Eudragit
NE30D is a coating material, and Radix Notoginseng total arasaponins makes Radix Notoginseng total arasaponins powder coating granule by powder coating, makes disintegrating tablet with other component mixing, tabletting again.
2. the preparation method of the described oral disintegrant tablet of total arasaponin of claim 1 is characterized in that being made up of following steps:
The first step is got coating material, uses suitable solvent dissolving and be diluted to debita spissitudo standby;
Second step got Radix Notoginseng total arasaponins and places ebullated bed to make boiling, and the solution that sprays into the first step with suitable speed carries out powder coating then, Radix Notoginseng total arasaponins powder coating granule, dry back sieving for standby;
The 3rd step with the second back coated granule mixing that sieves that goes on foot, added magnesium stearate, mixing again with mannitol, micropowder silica gel, crospolyvinylpyrrolidone, aspartame, ginseng essence mixing;
The 4th step the 3rd step gained material detects through intermediate, determine that sheet is heavy after, send into the tablet machine tabletting promptly.
3. preparation method according to claim 2, wherein, described solvent is the medicinal industrial alcohol more than 95%.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100497769A CN1250228C (en) | 2004-06-29 | 2004-06-29 | Orally disintegrating tablet of notoginsen total saponins and its preparation |
| PCT/CN2005/000171 WO2006000137A1 (en) | 2004-06-29 | 2005-02-06 | Oral disintegrable tablet of notogingseng total sapoin and the preparation process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100497769A CN1250228C (en) | 2004-06-29 | 2004-06-29 | Orally disintegrating tablet of notoginsen total saponins and its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1593439A CN1593439A (en) | 2005-03-16 |
| CN1250228C true CN1250228C (en) | 2006-04-12 |
Family
ID=34665828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100497769A Expired - Fee Related CN1250228C (en) | 2004-06-29 | 2004-06-29 | Orally disintegrating tablet of notoginsen total saponins and its preparation |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN1250228C (en) |
| WO (1) | WO2006000137A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100384428C (en) * | 2005-05-19 | 2008-04-30 | 郭爱华 | Oral disintegrating tablet of notoginseng triterpenes and preparation method thereof |
| CN100337615C (en) * | 2005-05-19 | 2007-09-19 | 郭鸿旭 | Oral disintegration tablet prepared from general saponin of notoginseng for treating thrombosis, and preparing technique |
| CN100374119C (en) * | 2005-09-21 | 2008-03-12 | 重庆康刻尔制药有限公司 | Pseudo-ginseng saponin oral disintegration tablet and preparing method |
| CN105641008A (en) * | 2016-01-27 | 2016-06-08 | 韩志强 | Pseudo-ginseng tablets and preparation method thereof |
| CN110025623A (en) * | 2019-03-21 | 2019-07-19 | 李和伟 | A kind of lyophilized preparation and its preparation method and application |
| CN114699384A (en) * | 2022-03-22 | 2022-07-05 | 中国科学院宁波材料技术与工程研究所 | A kind of drug taste masking method, drug and application thereof |
| CN116998574A (en) * | 2023-08-08 | 2023-11-07 | 云南贝泰妮生物科技集团股份有限公司 | Taste-masking micro-foam tablet and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1460517A (en) * | 2003-07-02 | 2003-12-10 | 北京博尔达生物技术开发有限公司 | Compound danshen oral disintegrant tablet and its preparation method |
| CN1237981C (en) * | 2003-12-31 | 2006-01-25 | 北京科信必成医药科技发展有限公司 | Ginkgoleaf oral cavity disintegrating tablet and its preparation method |
| CN1286480C (en) * | 2004-06-01 | 2006-11-29 | 广东天之骄生命科技有限公司 | Oral disintegrants of composite salvia miltiorrhiza and their preparation |
-
2004
- 2004-06-29 CN CNB2004100497769A patent/CN1250228C/en not_active Expired - Fee Related
-
2005
- 2005-02-06 WO PCT/CN2005/000171 patent/WO2006000137A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006000137A1 (en) | 2006-01-05 |
| CN1593439A (en) | 2005-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1250228C (en) | Orally disintegrating tablet of notoginsen total saponins and its preparation | |
| CN1237981C (en) | Ginkgoleaf oral cavity disintegrating tablet and its preparation method | |
| CN1824177A (en) | Medicinal composition for treating hypertension, its preparation method and use | |
| CN1247202C (en) | Dioscin oral disintegration tablet and its preparing method | |
| CN1443535A (en) | Tegasevod maleate oral preparation and its preparation process-for curing intestinal irritability syndrome | |
| CN1247203C (en) | Helicidum oral disintegation tablet and its preparing method | |
| CN1369306A (en) | 'Huajuhong' preparation and its preparing process | |
| CN1283267C (en) | Ginseng stem and leaf total saponin oral disintegration tablet and its preparing method | |
| CN1263457C (en) | Orally disintegrating tablet of gypenosides and its preparation process | |
| CN1267094C (en) | Orally disintegrating tablet of safflor yellow and its preparation process | |
| CN1297263C (en) | Calcium gluconate oral disintegrating tablet and its preparation process | |
| CN1872186A (en) | Compound capsule of Chinese date kernel, and preparation method | |
| CN1706372A (en) | Sodium ferulate orally disintegrating tablet and preparation method thereof | |
| CN1698873A (en) | Orally disintegrating tablet of 'Tianli Bolus' for treating heart disease and its preparation process | |
| CN1586516A (en) | Medicinal composition for treating cardiocerebral vasculr disease and its preparing method | |
| CN1040063C (en) | Application of zinc gluconate in preparing medicine for relieving asthma and cough | |
| CN1562060A (en) | Haw leaf total flavone oral disintegration tablet and its preparing method | |
| CN100336506C (en) | Orally disintegrating tablet of phentolamine mesylate and its preparation method | |
| CN1586596A (en) | American ginseng and its extract oral disintegration tablet and its preparing process | |
| CN1634390A (en) | Wilsonii oral disintegrating tablet and preparation method thereof | |
| CN1213749C (en) | Prepn. of obakulactone contd. medicine for treating hemorrhoid, and its use | |
| CN1903184A (en) | Effervesce tablets for treating liver diseases | |
| CN1895322A (en) | Jinganmin effervescent tablets and preparation thereof | |
| CN1785247A (en) | Disintegrant tablets, and its prepn. method | |
| CN101036681A (en) | Analgesic aconitum flavum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP02 | Change in the address of a patent holder |
Address after: 100083 Haidian District, Xueyuan Road, No. 30, A building, room No. 15, room, room 15 Patentee after: COSCI MED-TECH Co.,Ltd. Address before: 100086, Haidian District satellite building, No. 63, Zhichun Road, Beijing, room 1410, Beijing Patentee before: COSCI MED-TECH Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20191122 Address after: 1500008 3 / F, west side of building 13, Shuangtai Electric Power Industrial Park, No. 469, Xianfeng Road, Nangang District, Harbin City, Heilongjiang Province Patentee after: Harbin Kexin Bicheng Pharmaceutical Technology Development Co.,Ltd. Address before: 100083, Beijing, Xueyuan Road, Haidian District No. 30 Tiangong building, block A, room 15, room 15 Patentee before: COSCI MED-TECH Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060412 |